Oncology

Latest News

Highlights From ASCO 2024
ICYMI: Highlights From ASCO 2024

December 21st 2024

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

chemotherapy | Image credit: Penn Medicine
The High Cost of Shortages of Low-Cost Chemotherapy

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com
Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

December 17th 2024

FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com
Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

December 16th 2024

Highlights From COA 2024
ICYMI: Highlights From COA 2024

December 14th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Podcast: This Week in Managed Care—New Drug Pricing Probe and Other Health News
January 20th 2019

Podcast: This Week in Managed Care—New Drug Pricing Probe and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Dr Sibel Blau Discusses the Role of the Quality Cancer Care Alliance
January 20th 2019

Dr Sibel Blau Discusses the Role of the Quality Cancer Care Alliance

As the first clinically integrated oncology network, the Quality Cancer Care Alliance (QCCA) brings together the best practices and shares knowledge on value-based care, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy
January 19th 2019

Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy

Jaime Rosenberg
Higher tumor mutational burden is associated with improved overall survival in patients with stage IV or metastatic disease being treated with immune checkpoint inhibitors.
Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose
January 19th 2019

Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose

Laura Joszt, MA
Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients. In an analysis of 2 studies, patients with high-risk MM had improved outcomes when taking carfilzomib once a week compared with a twice-weekly dose.
Site Logo
January 19th 2019

AJMCtv® Interviews, January 2019

Samantha DiGrande Jaime Rosenberg
AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.
Site Logo
January 19th 2019

Policy

Updates from the annual ASH meeting, December 2018.
This Week in Managed Care: January 18, 2019
January 18th 2019

This Week in Managed Care: January 18, 2019

This week, the top managed care news included a new investigation into drug prices; FDA Commissioner Scott Gottlieb, MD, provided updates on how the government shutdown is impacting FDA work; research found comorbidities impede clinical trial participation for patients with cancer.
Site Logo
January 18th 2019

Quality of Life

Updates from the annual ASH meeting, December 2018.
USPSTF Releases Draft Recommendation on Drugs to Lower Risk of Breast Cancer
January 18th 2019

USPSTF Releases Draft Recommendation on Drugs to Lower Risk of Breast Cancer

Samantha DiGrande
Earlier this week, the US Preventive Services Task Force (USPSTF) released a draft guidance recommendations on medications for women at an increased risk for breast cancer.
Site Logo
January 18th 2019

Cost of Care: Biosimilars

Updates from the annual ASH meeting, December 2018.
Site Logo
January 18th 2019

Cost of Care

Updates from the annual ASH meeting, December 2018.
Site Logo
January 17th 2019

Clinical: Lymphoma

Updates from the annual ASH meeting, December 2018.
Site Logo
January 17th 2019

Clinical: Myelofibrosis

Updates from annual ASH meeting, December 2018.
Site Logo
January 17th 2019

Clinical: Chronic Lymphocytic Leukemia

Updates from the annual ASH meeting, December 2018.
Site Logo
January 17th 2019

Clinical: Multiple Myeloma

Updates from the annual ASH meeting, December 2018.
Site Logo
January 17th 2019

Clinical: CAR T-Cell Therapy

Updates from the Annual ASH meeting, December 2018.
African American Women Are at a Disadvantage in Preventing Breast Cancer
January 16th 2019

African American Women Are at a Disadvantage in Preventing Breast Cancer

Kelly Davio
Breast cancer risk estimation models identify women who are at high risk based on a variety of factors, and women who are identified as being at high risk may be able to reduce their chance of breast cancer through preventative measures such as prophylactic surgeries or chemoprevention medications. However, uptake of these preventative treatments varies among racial groups, new research from The Ohio State University finds that racial disparities in healthcare are to blame.
Comorbidities Impede Clinical Trial Participation Among Patients With Cancer
January 16th 2019

Comorbidities Impede Clinical Trial Participation Among Patients With Cancer

Jaime Rosenberg
Patients with cancer who have comorbidities are less likely to have clinical trial discussions, be offered a clinical trial, and participate in a clinical trial, according to a new study.
Podcast: This Week in Managed Care—Coverage From the JP Morgan Healthcare Conference and Other Health News
January 13th 2019

Podcast: This Week in Managed Care—Coverage From the JP Morgan Healthcare Conference and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: January 11, 2019
January 11th 2019

This Week in Managed Care: January 11, 2019

This week, the top managed care news included the FDA commissioner discussing boosting drug competition; BMS offering details on its acquisition of Celgene; and cancer mortality rates declining for the 25th consecutive year.
Cervical Cancer Screening Rates "Unacceptably Low," Researchers Find
January 10th 2019

Cervical Cancer Screening Rates "Unacceptably Low," Researchers Find

Jaime Rosenberg
Less than two-thirds of women aged 30 to 65 years were up to date with cervical cancer screenings in 2016. The percentage was even lower for women aged 21 to 29, with just over half up to date on screenings.
Cancer Mortality Rate Drops for the 25th Consecutive Year, but Socioeconomic Gap Widens
January 9th 2019

Cancer Mortality Rate Drops for the 25th Consecutive Year, but Socioeconomic Gap Widens

Kelly Davio
For the 25th consecutive year, the cancer mortality rate in the United States has declined, according to The American Cancer Society’s annual report on cancer rates and trends. The overall 27% drop in mortality rate translates into 2.6 million fewer deaths from cancer between the years 1991 and 2016.
What We're Reading: NYC Expands Health Coverage; Hospital Transparency Rule Confusion; Eli Lilly Purchases Loxo Oncology
January 9th 2019

What We're Reading: NYC Expands Health Coverage; Hospital Transparency Rule Confusion; Eli Lilly Purchases Loxo Oncology

AJMC Staff
New York City is expanding health coverage to 600,000 uninsured residents; a transparency rule requiring hospitals to post prices online is confusing patients; and Eli Lilly has purchased Loxo Oncology in what some are calling a massive bet on cancer genetic.
BMS, Celgene Discuss $74 Billion Acquisition During JP Morgan Healthcare Conference
January 8th 2019

BMS, Celgene Discuss $74 Billion Acquisition During JP Morgan Healthcare Conference

Jaime Rosenberg
Bristol-Meyers Squibb (BMS) and Celgene kicked off the 37th Annual JP Morgan Healthcare Conference by discussing their leading drugs, near-term launches, and early pipeline assets.
Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages
January 5th 2019

Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages

As a physician, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, was able to leverage his medical and scientific knowledge during treatment for his chronic lymphocytic leukemia (CLL), and he encourages other patients to educate themselves on their illnesses in order to receive the best care.
Dr Sibel Blau Explains What the Results of OCM Have Shown
December 31st 2018

Dr Sibel Blau Explains What the Results of OCM Have Shown

Results from the first 2 performance periods of the Oncology Care Model (OCM) highlighted areas where Northwest Medical Specialties was doing well and areas it could improve, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
Future of Therapy and Final Thoughts on Myelofibrosis
December 28th 2018

Future of Therapy and Final Thoughts on Myelofibrosis

Symptoms and Patient Progression
December 28th 2018

Symptoms and Patient Progression

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy
December 28th 2018

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy

Pacritinib and the Practical Implications
December 28th 2018

Pacritinib and the Practical Implications

<1
...
272829303132333435
...
181>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo